{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:51:43Z","timestamp":1791409903587,"version":"4.3.3"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002979","name":"Dalian Institute of Chemical Physics, Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["DICP UN202409"],"award-info":[{"award-number":["DICP UN202409"]}],"id":[{"id":"10.13039\/501100002979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002979","name":"Dalian Institute of Chemical Physics, Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["2024ZDJH01PT083"],"award-info":[{"award-number":["2024ZDJH01PT083"]}],"id":[{"id":"10.13039\/501100002979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012465","name":"Dalian Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2025-MSLH-200"],"award-info":[{"award-number":["2025-MSLH-200"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110251","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:37:45Z","timestamp":1784097465000},"page":"110251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Anticancer evaluation of novel chiral tetrahydropyrazolo[1,5-a]pyrimidine derivatives: Inhibitory effects on proliferation and migration of colon cancer cells with high HER2 expression"],"prefix":"10.1016","volume":"181","author":[{"given":"Dongwang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruidong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muwang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinsheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bioorg.2026.110251_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.110251_bb0010","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.canlet.2021.09.034","article-title":"Incidence, mortality, survival, risk factor and screening of colorectal cancer: a comparison among China, Europe, and Northern America","volume":"522","author":"Li","year":"2021","journal-title":"Cancer Lett."},{"issue":"10207","key":"10.1016\/j.bioorg.2026.110251_bb0015","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110251_bb0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7015","key":"10.1016\/j.bioorg.2026.110251_bb0025","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nature03095","article-title":"Targeted cancer therapy","volume":"432","author":"Sawyers","year":"2004","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110251_bb0030","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41392-024-01953-7","article-title":"Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110251_bb0035","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/bs.acr.2020.04.001","article-title":"HER family in cancer progression: from discovery to 2020 and beyond","volume":"147","author":"Kumar","year":"2020","journal-title":"Adv. Cancer Res."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110251_bb0040","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/0888-7543(89)90343-1","article-title":"Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32","volume":"4","author":"Popescu","year":"1989","journal-title":"Genomics"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110251_bb0045","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110251_bb0050","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2010.04.009","article-title":"The role of HER2 in cancer therapy and targeted drug delivery","volume":"146","author":"Tai","year":"2010","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110251_bb0055","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.drudis.2020.12.014","article-title":"Recent advances in HER2-targeted delivery for cancer therapy","volume":"26","author":"Dhritlahre","year":"2021","journal-title":"Drug Discov. Today"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110251_bb0060","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/modpathol.2015.98","article-title":"Assessment of a HER2 scoring system for colorectal cancer: results from a validation study","volume":"28","author":"Valtorta","year":"2015","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bioorg.2026.110251_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116101","article-title":"HER2 targeted therapy in colorectal Cancer: current landscape and future directions","volume":"223","author":"Chen","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110251_bb0070","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1007\/s00432-018-2744-z","article-title":"Variability in HER2 expression between primary colorectal cancer and corresponding metastases","volume":"144","author":"Shan","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110251_bb0075","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/annonc\/mdy156","article-title":"HER2 positive rates are enriched amongst colorectal cancer brain metastases: a study amongst 1920 consecutive patients","volume":"29","author":"Tan","year":"2018","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110251_bb0080","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s12094-019-02213-9","article-title":"Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer","volume":"22","author":"Wang","year":"2020","journal-title":"Clin. Transl. Oncol."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110251_bb0085","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nm0715-827b","article-title":"Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"Nat. Med."},{"issue":"99","key":"10.1016\/j.bioorg.2026.110251_bb0090","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002442","article-title":"Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab","volume":"3","author":"Yonesaka","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110251_bb0095","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1038\/bjc.2014.483","article-title":"HER2\/neu testing in primary colorectal carcinoma","volume":"111","author":"Ingold Heppner","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110251_bb0100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fonc.2012.00062","article-title":"Trastuzumab: updated mechanisms of action and resistance in breast cancer","volume":"2","author":"Vu","year":"2012","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110251_bb0105","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1158\/0008-5472.CAN-03-3856","article-title":"The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells","volume":"64","author":"Nahta","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110251_bb0110","article-title":"Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: results from the TAPUR study","volume":"6","author":"Gupta","year":"2022","journal-title":"JCO Precis. Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110251_bb0115","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/cas.15660","article-title":"Dual targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: a phase 2 trial","volume":"114","author":"Fu","year":"2023","journal-title":"Cancer Sci."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110251_bb0120","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2026.110251_bb0125","article-title":"Remarkable response of EGFR- and HER2-amplified metastatic colon cancer to pyrotinib after failed multiline treatments: a case report and literature review","volume":"10","author":"Li","year":"2020","journal-title":"Front. Oncol."},{"issue":"21","key":"10.1016\/j.bioorg.2026.110251_bb0130","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1158\/1078-0432.CCR-23-1041","article-title":"FDA approval summary: tucatinib with trastuzumab for advanced unresectable or metastatic, chemotherapy refractory, HER2-positive RAS wild-type colorectal cancer","volume":"29","author":"Casak","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110251_bb0135","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1039\/D2MD00192F","article-title":"Insights into the medicinal chemistry of heterocycles integrated with a pyrazolo[1,5-a]pyrimidine scaffold","volume":"13","author":"Hammouda","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110251_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.135877","article-title":"Synthesis, anticancer activity and molecular docking of new pyrazolo[1,5-a]pyrimidine derivatives as EGFR\/HER2 dual kinase inhibitors","volume":"1289","author":"Sivaiah","year":"2023","journal-title":"J. Mol. Struct."},{"issue":"18","key":"10.1016\/j.bioorg.2026.110251_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28186584","article-title":"NMR-verified dearomatization of 5,7-substituted pyrazolo[1,5-a]pyrimidines","volume":"28","author":"Novikova","year":"2023","journal-title":"Molecules"},{"issue":"17","key":"10.1016\/j.bioorg.2026.110251_bb0150","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of bruton\u2019s tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110251_bb0155","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cbpa.2010.06.168","article-title":"Targeted covalent drugs of the kinase family","volume":"14","author":"Singh","year":"2010","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110251_bb0160","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10637-023-01346-7","article-title":"Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines","volume":"41","author":"Dost\u00e1lov\u00e1","year":"2023","journal-title":"Invest. New Drugs"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110251_bb0165","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1021\/acs.joc.3c02396","article-title":"Iridium-catalyzed asymmetric hydrogenation of heteroaromatics with multiple N atoms via substrate activation: an entry to 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carbonitrile core of a potent BTK inhibitor","volume":"89","author":"Chen","year":"2024","journal-title":"J. Org. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110251_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/life12091403","article-title":"HER2 in metastatic colorectal cancer: pathology, somatic alterations, and perspectives for novel therapeutic schemes","volume":"12","author":"Ivanova","year":"2022","journal-title":"Life"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110251_bb0175","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"18","key":"10.1016\/j.bioorg.2026.110251_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810172","article-title":"Novel insights into epigenetic regulation of IL6 pathway: in silico perspective on inflammation and cancer relationship","volume":"22","author":"Candido","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.bioorg.2026.110251_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22136813","article-title":"Beyond RAS and BRAF: HER2, a new actionable oncotarget in advanced colorectal cancer","volume":"22","author":"Guarini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"65","key":"10.1016\/j.bioorg.2026.110251_bb0190","doi-asserted-by":"crossref","first-page":"39542","DOI":"10.1039\/D0RA07716J","article-title":"Pyrazolo[1,5-a]pyrimidines-based fluorophores: a comprehensive theoretical-experimental study","volume":"10","author":"Tigreros","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110251_bb0195","first-page":"5059","article-title":"Inhibition of lung cancer cells A549 and H460 by curcuminoid extracts and nanoemulsions prepared from Curcuma longa Linnaeus","volume":"10","author":"Chang","year":"2015","journal-title":"Int. J. Nanomedicine"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110251_bb0200","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40659-020-00301-7","article-title":"\u03b2-Catenin: oncogenic role and therapeutic target in cervical cancer","volume":"53","author":"Wang","year":"2020","journal-title":"Biol. Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110251_bb0205","doi-asserted-by":"crossref","first-page":"2251696","DOI":"10.1080\/21655979.2023.2251696","article-title":"\u03b2-Catenin inhibitors in cancer therapeutics: intricacies and way forward","volume":"14","author":"Dev","year":"2023","journal-title":"Bioengineered"},{"issue":"9","key":"10.1016\/j.bioorg.2026.110251_bb0210","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","article-title":"HER2-targeted therapies beyond breast cancer - an update","volume":"21","author":"Yoon","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110251_bb0215","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3892\/ijo.2015.3157","article-title":"Toosendanin inhibits growth and induces apoptosis in colorectal cancer cells through suppression of AKT\/GSK-3\u03b2\/\u03b2-catenin pathway","volume":"47","author":"Wang","year":"2015","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110251_bb0220","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies - a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110251_bb0225","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11745-011-3649-7","article-title":"The \u201cHER2-PI3K\/Akt-FASN Axis\u201d regulated malignant phenotype of colorectal cancer cells","volume":"47","author":"Li","year":"2012","journal-title":"Lipids"},{"issue":"8","key":"10.1016\/j.bioorg.2026.110251_bb0230","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41419-023-06073-8","article-title":"A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway","volume":"14","author":"Wu","year":"2023","journal-title":"Cell Death Dis."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110251_bb0235","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.3390\/molecules26092708","article-title":"Functional pyrazolo[1,5-a]pyrimidines: current approaches in synthetic transformations and uses as an antitumor scaffold","volume":"26","author":"Arias-G\u00f3mez","year":"2021","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110251_bb0240","doi-asserted-by":"crossref","first-page":"760","DOI":"10.2174\/156802611795165098","article-title":"The significance of chirality in drug design and development","volume":"11","author":"Brooks","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110251_bb0245","first-page":"45","article-title":"HER2-positive male breast cancer: an update","volume":"2","author":"Ottini","year":"2010","journal-title":"Breast Cancer (Dove Med Press)."},{"issue":"24","key":"10.1016\/j.bioorg.2026.110251_bb0250","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038508","article-title":"HER2\/PI3K\/AKT pathway in HER2-positive breast cancer: a review","volume":"103","author":"Pan","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110251_bb0255","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10120-024-01478-6","article-title":"Elucidating molecular mechanisms and therapeutic synergy: irreversible HER2-TKI plus T-Dxd for enhanced anti-HER2 treatment of gastric cancer","volume":"27","author":"Liu","year":"2024","journal-title":"Gastric Cancer"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110251_bb0260","article-title":"The Lyn\/RUVBL1 complex promotes colorectal cancer liver metastasis by regulating arachidonic acid metabolism through chromatin remodeling","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv Sci (Weinh)."},{"issue":"15","key":"10.1016\/j.bioorg.2026.110251_bb0265","doi-asserted-by":"crossref","first-page":"11221","DOI":"10.1074\/jbc.M611871200","article-title":"Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity","volume":"282","author":"Fang","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110251_bb0270","doi-asserted-by":"crossref","DOI":"10.1186\/s12929-022-00860-9","article-title":"Akt: a key transducer in cancer","volume":"29","author":"Tsai","year":"2022","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110251_bb0275","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41418-019-0361-2","article-title":"DC-SIGN-LEF1\/TCF1-miR-185 feedback loop promotes colorectal cancer invasion and metastasis","volume":"27","author":"Yuan","year":"2020","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110251_bb0280","article-title":"Neratinib enhances the efficacy of CDK4\/6 inhibitor plus endocrine therapy in HR+\/HER2-low breast cancer cell line ZR-75-1 via hsa-miR-23a-5p","volume":"14","author":"Chen","year":"2024","journal-title":"Sci. Rep."},{"issue":"15","key":"10.1016\/j.bioorg.2026.110251_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27155002","article-title":"Transcriptome analysis of the anti-proliferative effects of ginsenoside Rh3 on HCT116 colorectal cancer cells","volume":"27","author":"Teng","year":"2022","journal-title":"Molecules"},{"issue":"W1","key":"10.1016\/j.bioorg.2026.110251_bb0290","doi-asserted-by":"crossref","first-page":"W432","DOI":"10.1093\/nar\/gkae298","article-title":"admetSAR3.0: a comprehensive platform for exploration, prediction and optimization of chemical ADMET properties","volume":"52","author":"Gu","year":"2024","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110251_bb0295","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-023-04499-4","article-title":"A diagnostic model for sepsis-induced acute lung injury using a consensus machine learning approach and its therapeutic implications","volume":"21","author":"Zheng","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bioorg.2026.110251_bb0300","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.2147\/JIR.S474984","article-title":"Unraveling shared diagnostic biomarkers of fibromyalgia in ankylosing spondylitis: evidence from comprehensive bioinformatic analysis and experimental validation","volume":"17","author":"Bi","year":"2024","journal-title":"J. Inflamm. Res."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110251_bb0305","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1021\/acs.jcim.6c00014","article-title":"WeMol: a cloud-based and zero-code platform for AI-driven molecular design and simulation","volume":"66","author":"Liu","year":"2026","journal-title":"J. Chem. Inf. Model."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600787X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600787X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:13:24Z","timestamp":1791407604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682600787X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":61,"alternative-id":["S004520682600787X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110251","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticancer evaluation of novel chiral tetrahydropyrazolo[1,5-a]pyrimidine derivatives: Inhibitory effects on proliferation and migration of colon cancer cells with high HER2 expression","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110251"}}